IDH1-R132 changes vary according to NPM1 and other mutations status in AML
Open Access
- 8 January 2019
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 33 (4) , 1043-1047
Abstract
No abstract availableKeywords
Funding Information
- EC | European Research Council (ERC Adv Grant 2016 n. 740230)
- Associazione Italiana per la Ricerca sul Cancro (AIRC IG 2016 n.18568)
This publication has 15 references indexed in Scilit:
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategiesLeukemia, 2018
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood, 2015
- Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical OpportunitiesCancer Discovery, 2013
- IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 statusBlood, 2010
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationCancer Cell, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsJournal of Experimental Medicine, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Monoclonal antibody specific for IDH1 R132H mutationActa Neuropathologica, 2009